Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Marijke Wasielewski"'
Autor:
Mieke Schutte, Fons Elstrodt, Linda B C Bralten, Jord H A Nagel, Elza Duijm, Antoinette Hollestelle, Maartje J Vuerhard, Marijke Wasielewski, Justine K Peeters, Peter van der Spek, Peter A Sillevis Smitt, Pim J French
Publikováno v:
PLoS ONE, Vol 3, Iss 8, p e3007 (2008)
BACKGROUND: Identification of genes that are causally implicated in oncogenesis is a major goal in cancer research. An estimated 10-20% of cancer-related gene mutations result in skipping of one or more exons in the encoded transcripts. Here we repor
Externí odkaz:
https://doaj.org/article/643fafb4ae6e4f71a382f8722e3eed19
Autor:
Mieke Schutte, Stephen P. Ethier, Sofia D. Merajver, Ans van den Ouweland, Marijke Wasielewski, Michael Gorin, Jord H.A. Nagel, Antoinette Hollestelle, Fons Elstrodt
Supplementary Figure S2 from BRCA1 Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious Mutants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d38f146bff03f6e00723fe52caced057
https://doi.org/10.1158/0008-5472.22365296.v1
https://doi.org/10.1158/0008-5472.22365296.v1
Autor:
Mieke Schutte, Stephen P. Ethier, Sofia D. Merajver, Ans van den Ouweland, Marijke Wasielewski, Michael Gorin, Jord H.A. Nagel, Antoinette Hollestelle, Fons Elstrodt
Germ line mutations of the BRCA1 gene confer a high risk of breast cancer and ovarian cancer to female mutation carriers. The BRCA1 protein is involved in the regulation of DNA repair. How specific tumor-associated mutations affect the molecular func
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4225517ebd04c5032b1882b3e0473fb
https://doi.org/10.1158/0008-5472.c.6494630
https://doi.org/10.1158/0008-5472.c.6494630
Autor:
Mieke Schutte, Stephen P. Ethier, Sofia D. Merajver, Ans van den Ouweland, Marijke Wasielewski, Michael Gorin, Jord H.A. Nagel, Antoinette Hollestelle, Fons Elstrodt
Supplementary Figure Legends from BRCA1 Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious Mutants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::465d57e52d999e8354107e018b96ebf9
https://doi.org/10.1158/0008-5472.22365302
https://doi.org/10.1158/0008-5472.22365302
Autor:
Hanne Meijers-Heijboer, Jan G. M. Klijn, Juul T. Wijnen, Dennis Dooijes, Carli M. J. Tops, Mieke Schutte, Hans F. A. Vasen, Maartje J. Hooning, Marijke Wasielewski
Publikováno v:
Clinical Cancer Research, 14(15), 4989-4994. American Association for Cancer Research Inc.
Clinical cancer research, 14(15), 4989-4994. American Association for Cancer Research Inc.
Clinical cancer research, 14(15), 4989-4994. American Association for Cancer Research Inc.
Purpose: The pathogenic CHEK2 1100delC variant is firmly established as a breast cancer susceptibility allele. Dutch CHEK2 1100delC breast cancer families frequently also include colorectal cancer cases, and the variant is particularly prevalent amon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba8de3c12643034eaf1a03983386f9e8
https://doi.org/10.1158/1078-0432.ccr-08-0389
https://doi.org/10.1158/1078-0432.ccr-08-0389
Autor:
Ans M.W. van den Ouweland, Cecile T. M. Brekelmans, Mieke Schutte, Jan G. M. Klijn, Jord H. A. Nagel, Hanne Meijers-Heijboer, Marijke Wasielewski
Publikováno v:
Breast cancer research and treatment, 104(2), 153-157. Springer New York
Breast Cancer Research and Treatment, 104(2), 153-157. Springer New York
Breast Cancer Research and Treatment, 104(2), 153-157. Springer New York
A single nucleotide polymorphism (SNP309T>G) in the intronic promoter of MDM2 was recently found to accelerate carcinogenesis in early-onset cancer cases. This cancer acceleration presumably was due to increased SP1 binding, resulting in enhanced MDM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ceca2a17b45b035ba009ccee1552a67
https://doi.org/10.1007/s10549-006-9407-5
https://doi.org/10.1007/s10549-006-9407-5
Autor:
Sheila Seal, Barbara L. Weber, Jenny Chang-Claude, Lesley McGuffog, Jan Klijn, Rosalind A. Eeles, P. Andrew Futreal, Katherine L. Nathanson, Nazneen Rahman, Rita Barfoot, Mieke Schutte, Richard S. Houlston, Michael R. Stratton, Deborah J. Thompson, Anthony Renwick, Hanne Meijers-Heijboer, Marijke Wasielewski, Douglas F. Easton, Nayanta Sodha, Susan Shanley
Publikováno v:
Cancer epidemiology, biomarkers & prevention, 15(12), 2542-2545. American Association for Cancer Research Inc.
Cancer Epidemiology Biomarkers & Prevention, 15, 2542-2545. American Association for Cancer Research Inc.
Cancer Epidemiology Biomarkers & Prevention, 15, 2542-2545. American Association for Cancer Research Inc.
The CHEK2 1100delC protein-truncating mutation has a carrier frequency of ∼0.7% in Northern and Western European populations and confers an ∼2-fold increased risk of breast cancer. It has also been suggested to increase risks of colorectal and pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31847397c9a168963f15a9f9b8bd0145
https://doi.org/10.1158/1055-9965.epi-06-0687
https://doi.org/10.1158/1055-9965.epi-06-0687
Publikováno v:
Breast Cancer Research and Treatment, 99(1), 97-101. Springer New York
The p53 tumor suppressor gene is frequently mutated in breast cancer. Here, we used direct sequencing to screen the complete coding sequence of the p53 gene from 41 human breast cancer cell lines. We identified 32 cell lines (78%) with a p53 gene alt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aba70b9e830094c6feba6697a4ac116
https://pure.eur.nl/en/publications/a2f68c57-2565-4b8a-9cb4-8f633526b638
https://pure.eur.nl/en/publications/a2f68c57-2565-4b8a-9cb4-8f633526b638
Autor:
Mieke Schutte, Ivonne J. H. M. van Minderhout, Peter Devilee, Petra E A Huijts, Juul T. Wijnen, Martijn H. Breuning, Caroline Seynaeve, Maartje Nielsen, Astrid A. Out, Frederik J. Hes, Christi J. van Asperen, Jeanine J. Houwing-Duistermaat, Carli M. J. Tops, Marijke Wasielewski
Publikováno v:
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 134(1), 219-227. Springer New York
Breast Cancer Research and Treatment, 134(1), 219-227
Out, A A, Wasielewski, M, Huijts, P E A, van Minderhout, I J H M, Houwing-Duistermaat, J J, Tops, C M J, Nielsen, M, Seynaeve, C, Wijnen, J T, Breuning, M H, van Asperen, C J, Schutte, M, Hes, F J & Devilee, P 2012, ' MUTYH gene variants and breast cancer in a Dutch case-control study ', Breast Cancer Research and Treatment, vol. 134, no. 1, pp. 219-227 . https://doi.org/10.1007/s10549-012-1965-0
Breast Cancer Research and Treatment, 134(1), 219-227. Springer New York
Breast Cancer Research and Treatment, 134(1), 219-227
Out, A A, Wasielewski, M, Huijts, P E A, van Minderhout, I J H M, Houwing-Duistermaat, J J, Tops, C M J, Nielsen, M, Seynaeve, C, Wijnen, J T, Breuning, M H, van Asperen, C J, Schutte, M, Hes, F J & Devilee, P 2012, ' MUTYH gene variants and breast cancer in a Dutch case-control study ', Breast Cancer Research and Treatment, vol. 134, no. 1, pp. 219-227 . https://doi.org/10.1007/s10549-012-1965-0
The MUTYH gene is involved in base excision repair. MUTYH mutations predispose to recessively inherited colorectal polyposis and cancer. Here, we evaluate an association with breast cancer (BC), following up our previous finding of an elevated BC fre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e85ca7cac9b6838bb5cab539a3a9d02
https://pubmed.ncbi.nlm.nih.gov/22297469
https://pubmed.ncbi.nlm.nih.gov/22297469
Autor:
Hanne Meijers-Heijboer, Anita M. A. C. Trapman-Jansen, Jan G. M. Klijn, Marijke Wasielewski, Wilfred F. J. van IJcken, Vanja de Weerd, Jord H. A. Nagel, Hennie T. Brüggenwirth, John A. Foekens, Anieta M. Sieuwerts, Ans M.W. van den Ouweland, Justine K. Peeters, Marcel Smid, Mieke Schutte, Peter J. van der Spek, John W.M. Martens
Publikováno v:
Breast Cancer Research and Treatment, 132(2), 439-448. Springer New York
Breast cancer research and treatment, 132(2), 439-448. Springer New York
Nagel, J H A, Peeters, J K, Smid, M, Sieuwerts, A M, Wasielewski, M, de Weerd, V, Trapman-Jansen, A M A C, van den Ouweland, A, Bruggenwirth, H, van Ijcken, W F J, Klijn, J G M, van der Spek, P J, Foekens, J A, Martens, J W M, Schutte, M & Meijers-Heijboer, E J 2012, ' Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes ', Breast Cancer Research and Treatment, vol. 132, no. 2, pp. 439-448 . https://doi.org/10.1007/s10549-011-1588-x
Breast cancer research and treatment, 132(2), 439-448. Springer New York
Nagel, J H A, Peeters, J K, Smid, M, Sieuwerts, A M, Wasielewski, M, de Weerd, V, Trapman-Jansen, A M A C, van den Ouweland, A, Bruggenwirth, H, van Ijcken, W F J, Klijn, J G M, van der Spek, P J, Foekens, J A, Martens, J W M, Schutte, M & Meijers-Heijboer, E J 2012, ' Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes ', Breast Cancer Research and Treatment, vol. 132, no. 2, pp. 439-448 . https://doi.org/10.1007/s10549-011-1588-x
CHEK2 1100delC is a moderate-risk cancer susceptibility allele that confers a high breast cancer risk in a polygenic setting. Gene expression profiling of CHEK2 1100delC breast cancers may reveal clues to the nature of the polygenic CHEK2 model and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d21d521db68519591a528cc32db9f825
https://pubmed.ncbi.nlm.nih.gov/21614566
https://pubmed.ncbi.nlm.nih.gov/21614566